Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hydroxychloroquine and systemic lupus: a reappraisal].

N Costedoat-Chalumeau1, G Leroux, Z Amoura

  • 1université de Pierre-et-Marie-Curie-Paris-6, centre de référence national pour les lupus et le syndrome des antiphospholipides, centre hospitalier universitaire de la Pitié-Salpêtrière, Paris, France. nathalie.costedoat@psl.aphp.fr

La Revue De Medecine Interne
|July 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Belimumab and alopecia areata: No clear safety signal in a multicentre case series and pharmacovigilance analysis.

Annales de dermatologie et de venereologie·2026
Same author

Diffuse alveolar hemorrhage in antiphospholipid syndrome: Clinical presentation and prognosis.

Respiratory medicine·2026
Same author

Outcome and prognosis of isolated carotid vasculitis.

Journal of autoimmunity·2024
Same author

Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study.

American journal of hematology·2024
Same author

French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children.

La Revue de medecine interne·2023
Same author

French practical guidelines for the diagnosis and management of relapsing polychondritis.

La Revue de medecine interne·2023
Same journal

[Atypical low back pain].

La Revue de medecine interne·2026
Same journal

[Polycythemia associated chronic haemolysis].

La Revue de medecine interne·2026
Same journal

[Persistent headaches in a 55 year-old man].

La Revue de medecine interne·2026
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
See all related articles

Hydroxychloroquine (HCQ) is a highly effective and safe first-line treatment for systemic lupus erythematosus (SLE). Its favorable efficacy and safety profile, low cost, and proven benefits in reducing flares and complications support its widespread use in SLE management.

Area of Science:

  • Rheumatology
  • Pharmacology

Context:

  • Systemic lupus erythematosus (SLE) management often involves suboptimal treatment strategies.
  • Hydroxychloroquine (HCQ) is frequently underutilized as a second-line therapy.

Purpose:

  • To highlight the benefits of Hydroxychloroquine (HCQ) as a first-line treatment for SLE.
  • To advocate for the broader prescription of HCQ based on its efficacy and safety profile.

Summary:

  • Hydroxychloroquine (HCQ) demonstrates significant efficacy in reducing SLE flares and overall damage.
  • HCQ offers protective effects against thrombotic events, low bone mineral density, and improves lipid profiles.
  • The drug possesses a favorable efficacy/toxicity ratio, is cost-effective, and has a reliable blood assay.

Impact:

Related Experiment Videos

  • Widespread adoption of HCQ can significantly improve the management and outcomes for SLE patients.
  • Increased utilization of HCQ may lead to better long-term survival rates in individuals with SLE.
  • While rare, regular screening for retinopathy is necessary, though guidelines require consensus.